APA (7th ed.) Citation

A, G., C, J., A, B., S, K., T, I., K, L., & J, R. (2013). Brentuximab vedotin in refractory CD30+ lymphomas: A bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica, 98(4), 611. https://doi.org/10.3324/haematol.2012.069393

Chicago Style (17th ed.) Citation

A, Gibb, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, and Radford J. "Brentuximab Vedotin in Refractory CD30+ Lymphomas: A Bridge to Allogeneic Transplantation in Approximately One Quarter of Patients Treated on a Named Patient Programme at a Single UK Center." Haematologica 98, no. 4 (2013): 611. https://doi.org/10.3324/haematol.2012.069393.

MLA (9th ed.) Citation

A, Gibb, et al. "Brentuximab Vedotin in Refractory CD30+ Lymphomas: A Bridge to Allogeneic Transplantation in Approximately One Quarter of Patients Treated on a Named Patient Programme at a Single UK Center." Haematologica, vol. 98, no. 4, 2013, p. 611, https://doi.org/10.3324/haematol.2012.069393.